- Home
- PTA vs RXST Comparison
PTA vs RXST Comparison
Compare PTA & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTA
- RXST
- Stock Information
- Founded
- PTA 2020
- RXST 1997
- Country
- PTA United States
- RXST United States
- Employees
- PTA N/A
- RXST N/A
- Industry
- PTA Trusts Except Educational Religious and Charitable
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PTA Finance
- RXST Health Care
- Exchange
- PTA Nasdaq
- RXST Nasdaq
- Market Cap
- PTA 1.1B
- RXST 1.0B
- IPO Year
- PTA N/A
- RXST 2021
- Fundamental
- Price
- PTA $19.42
- RXST $25.25
- Analyst Decision
- PTA
- RXST Strong Buy
- Analyst Count
- PTA 0
- RXST 9
- Target Price
- PTA N/A
- RXST $49.33
- AVG Volume (30 Days)
- PTA 159.2K
- RXST 541.6K
- Earning Date
- PTA 01-01-0001
- RXST 05-05-2025
- Dividend Yield
- PTA 8.31%
- RXST N/A
- EPS Growth
- PTA N/A
- RXST N/A
- EPS
- PTA N/A
- RXST N/A
- Revenue
- PTA N/A
- RXST $139,927,000.00
- Revenue This Year
- PTA N/A
- RXST $38.53
- Revenue Next Year
- PTA N/A
- RXST $24.60
- P/E Ratio
- PTA N/A
- RXST N/A
- Revenue Growth
- PTA N/A
- RXST 57.09
- 52 Week Low
- PTA $15.84
- RXST $24.09
- 52 Week High
- PTA $19.67
- RXST $66.54
- Technical
- Relative Strength Index (RSI)
- PTA 42.55
- RXST 40.99
- Support Level
- PTA $19.28
- RXST $24.24
- Resistance Level
- PTA $19.87
- RXST $27.13
- Average True Range (ATR)
- PTA 0.24
- RXST 1.05
- MACD
- PTA 0.00
- RXST 0.32
- Stochastic Oscillator
- PTA 40.00
- RXST 38.16
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.